Phosphodiesterase 5 inhibitors in vascular systemic disorders

被引：4
作者：
Allanore, Yannick [1 ]
机构：
[1] Univ Paris 05, INSERM U1016, Serv Rhumatol, Hop Cochin, F-75014 Paris, France
来源：
JOINT BONE SPINE | 2012年 / 79卷 / 04期
关键词：
Phosphodiesterase; Nitric oxide; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Tadalafil; PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON RESISTANT; DOUBLE-BLIND; SILDENAFIL; THERAPY; TADALAFIL; SCLEROSIS; EFFICACY;
D O I：
10.1016/j.jbspin.2011.12.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 340
页数：3
相关论文
共 50 条
[41]   Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction [J].
Mulhall, JP ;
Montorsi, F .
EUROPEAN UROLOGY, 2006, 49 (01) :30-37
[42]   Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors [J].
Taylor, Joby ;
Baldo, Omer B. ;
Storey, Anne ;
Cartledge, Jon ;
Eardley, Ian .
BJU INTERNATIONAL, 2009, 103 (10) :1392-1395
[43]   RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors [J].
Hoeper, Marius M. ;
Simonneau, Gerald ;
Corris, Paul A. ;
Ghofrani, Hossein-Ardeschir ;
Klinger, James R. ;
Langleben, David ;
Naeije, Robert ;
Jansa, Pavel ;
Rosenkranz, Stephan ;
Scelsi, Laura ;
Gruenig, Ekkehard ;
Vizza, Carmine Dario ;
Chang, MiKyung ;
Colorado, Pablo ;
Meier, Christian ;
Busse, Dennis ;
Benza, Raymond L. .
EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (03)
[44]   Comparison of phosphodiesterase type 5 (PDE5) inhibitors [J].
Wright, P. J. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) :967-975
[45]   Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection? [J].
Mostafa, Taymour .
SEXUAL MEDICINE REVIEWS, 2021, 9 (01) :15-22
[46]   Study of the efficacy and preferences among severe erectile dysfunction patients after taking 3 phosphodiesterase 5 inhibitors [J].
Rodriguez-Tolra, Josep ;
Cuadrado Campana, Jose Maria ;
Torremade Barreda, Jose ;
Llorens de Knecht, Erika ;
Franco Miranda, Eladio .
REVISTA INTERNACIONAL DE ANDROLOGIA, 2012, 10 (04) :139-146
[47]   Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men [J].
Li, Jinhong ;
Shi, Qingquan ;
Pu, Chunxiao ;
Tang, Yin ;
Bai, Yunjin ;
Yuan, Haichao ;
Li, Xiang ;
Dong, Qiang ;
Wei, Qiang ;
Yuan, Jiuhong ;
Han, Ping .
SCIENTIFIC REPORTS, 2014, 4
[48]   The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: A critical analysis of basic science and clinical data [J].
Chen, Juza ;
Keren-Paz, Gal ;
Bar-Yosef, Yuval ;
Matzkin, Haim .
EUROPEAN UROLOGY, 2007, 52 (05) :1331-1339
[49]   Phosphodiesterase Type 5 Inhibitors as Adjunctive Therapy in the Management of Systolic Heart Failure [J].
Cvelich, Ramonna G. ;
Roberts, Sarah C. ;
Brown, Jamie N. .
ANNALS OF PHARMACOTHERAPY, 2011, 45 (12) :1551-1558
[50]   Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets [J].
Bajraktari, Grona ;
Burhenne, Juergen ;
Bugert, Peter ;
Haefeli, Walter Emil ;
Weiss, Johanna .
BIOCHEMICAL PHARMACOLOGY, 2017, 145 :54-63
12345